Flagship Pioneering adds a new $824M biotech growth fund

In 2018, Flagship backed its companies to the tune of $294 million, launching five companies and unveiling three others that had been operating quietly. (Flagship Pioneering)

Flagship Pioneering has raised $824 million for a new fund to support biotech and health companies that have come up through its Flagship Labs foundry. The capital comes from “new institutional investors and family officers” as well as “long-time limited partners” and follows a similar fund closed in 2016. 

Now, Flagship Pioneering plans to grow its team of executive partners and “provide additional growth resources to our ecosystem of companies,” said Noubar Afeyan, Ph.D., Flagship’s CEO and founder, in a statement. The capital will join more than $700 million raised over the last couple of years that bankrolls Flagship’s in-house innovation and company-creating activities, the company said. 

The new fund, dubbed the Special Opportunities Fund II, eclipsed its predecessor, the Special Opportunities Fund I, which raised $285 million in 2016. 


Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

RELATED: Flagship Pioneering gains $618M for life science investment push 

"With each year of company origination, as we have honed our pioneering approach, we have steadily increased our capacity to launch transformative ventures," Afeyan said. "Our new fund will complement our origination capabilities with new capital to grow platform companies more rapidly.”

In 2018, Flagship backed its companies to the tune of $294 million. It launched five new companies and saw four of its companies go public: Rubius Therapeutics, Evelo Biosciences, Kaleido Biosciences and Moderna Therapeutics. Three of its companies also came out of stealth last year, including Foghorn Therapeutics, a biotech working to understand the body’s chromatin regulatory system in order to create drugs for cancer and other diseases. 

And Flagship is showing no signs of letting up in 2019. In January, it launched a cancer startup, Cygnal, which had spent two years in its foundry. Pearl Huang, the former SVP at Roche and BeiGene founder will lead the biotech as it develops drugs targeting the peripheral nervous system for cancer and other diseases.

Suggested Articles

Janssen is planning its first completely virtual clinical trial, using personal smartphones and wearable devices with no in-person site visits.

Sensyne Health aims to bring its AI tools to America, and it’s enlisting IT giant Cognizant and data infrastructure specialist Agorai to help.

Californian RNA biotech Arrowhead will lose its COO and R&D head from next year but is hiring a new CMO and CSO to help steady its research exec team.